Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	615.00M -4.5%
Revenue (ttm)	90.41M -0.8%
Net Income	-118.69M
EPS	-5.14
Shares Out	23.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,794
Average Volume	26,720
Open	26.60
Previous Close	26.60
Day's Range	26.00 - 27.05
52-Week Range	17.62 - 36.00
Beta	0.50
RSI	55.93
Earnings Date	Mar 13, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 328
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2024, Ryvu Therapeutics's revenue was 101.96 million, an increase of 51.51% compared to the previous year's 67.30 million. Losses were -111.44 million, 21.0% more than in 2023.